4.7 Review

Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements

期刊

AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 107, 期 2, 页码 179-194

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1038/ajg.2011.386

关键词

-

资金

  1. Canadian Institutes of Health Research Institute of Nutrition, Metabolism, and Diabetes
  2. Abbott Canada (Montreal, Canada)
  3. Aptalis Pharma (Mont Saint-Hilaire, Canada)
  4. Janssen Inc. (Toronto, Canada)
  5. Shire Canada (Ville Saint-Laurent, Canada)
  6. UCB Pharma Canada (Oakville, Canada)
  7. Warner Chilcott (Toronto, Canada)
  8. Abbott
  9. Alba
  10. Albiero Pharma
  11. Aptalis
  12. Berlex
  13. Bristol-Myers Squibb
  14. Celgene
  15. Centocor
  16. Cerimon Pharma
  17. CombinatoRx
  18. Elan/Biogen
  19. Ferring
  20. GlaxoSmithKline
  21. GeneLogic Inc/Ore Pharma
  22. Genetech
  23. Genzyme
  24. Given Imaging
  25. ISIS
  26. Janssen-Ortho
  27. Millennium Research Group
  28. Napo Pharma
  29. Novartis
  30. Novo Nordisk
  31. Osiris Therapeutics
  32. Proctor & Gamble/Warner Chilcott
  33. Protein Design Labs
  34. Santarus
  35. Salax
  36. Shire
  37. Janssen
  38. Serono
  39. Synta
  40. Teva
  41. Tioga Pharma
  42. Tillotts
  43. UCB Pharma
  44. Unity Pharma
  45. Vertex
  46. VSL3
  47. Axcan
  48. ActoGenix
  49. Asahi Medical
  50. AstraZeneca
  51. Boehringer Engelheim
  52. Chemocentryx
  53. Nycomed
  54. Olympus America
  55. Otsuka
  56. Tillots

向作者/读者索取更多资源

OBJECTIVES: The objective of this study was to provide updated explicit and relevant consensus statements for clinicians to refer to when managing hospitalized adult patients with acute severe ulcerative colitis (UC). METHODS: The Canadian Association of Gastroenterology consensus group of 23 voting participants developed a series of recommendation statements that addressed pertinent clinical questions. An iterative voting and feedback process was used to do this in conjunction with systematic literature reviews. These statements were brought to a formal consensus meeting held in Toronto, Ontario (March 2010), when each statement was discussed, reformulated, voted upon, and subsequently revised until group consensus (at least 80% agreement) was obtained. The modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria were used to rate the strength of recommendations and the quality of evidence. RESULTS: As a result of the iterative process, consensus was reached on 21 statements addressing four themes (General considerations and nutritional issues, Steroid use and predictors of steroid failure, Cyclosporine and infliximab, and Surgical issues). CONCLUSIONS: Key recommendations for the treatment of hospitalized patients with severe UC include early escalation to second-line medical therapy with either infliximab or cyclosporine in individuals in whom parenteral steroids have failed after 72 h. These agents should be used in experienced centers where appropriate support is available. Sequential therapy with cyclosporine and infliximab is not recommended. Surgery is an option when first-line steroid therapy fails, and is indicated when second-line medical therapy fails and/or when complications arise during the hospitalization.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据